Anti-ATP-Citrate Lyase (C-term) Antibody

This unconjugated primary antibody from Antibodies.com targets the C-terminal region of ATP-Citrate Lyase (ACLY), a cytosolic enzyme that converts citrate into acetyl-CoA and oxaloacetate. Raised in mouse as an IgG2a monoclonal, the reagent is validated for Western blot, immunocytochemistry, and flow cytometry, and it cross-reacts with human, mouse, and rat samples, making it a useful reagent across comparative metabolic studies.

ACLY sits at a branch point linking glucose-derived citrate to de novo lipogenesis and to the acetyl-CoA pool that fuels histone acetylation, so the antibody is frequently deployed in cancer metabolism research, studies of hepatic steatosis, and investigations into chromatin regulation. The product is supplied as 100 µl of liquid in a vial, and aliquoting upon arrival is recommended to limit freeze-thaw cycles of the working stock.